Overexpression of CDCA8 predicts poor prognosis and drug insensitivity in lung adenocarcinoma - Gu, Huiquan; Gao, Xinzheng; Han, Wenlong; Wang, Fangyu; Zhang, Hanqiang; Yao, Longyu; Chen, Weimin; Liu, Qiang (BMC medical genomics, 2024)
Keywords: Adenocarcinoma; Adenocarcinoma of Lung - genetics; Adenocarcinoma of Lung - metabolism; Adenocarcinoma of Lung - pathology; Aged; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antineoplastic drugs; Biomarker; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Cancer; Cancer therapies; CDCA8; Cell cycle; Cell Cycle Proteins - genetics; Cell Cycle Proteins - metabolism; Cell division; Datasets; Diagnosis; Drug development; Drug resistance; Drug Resistance, Neoplasm - genetics; Drug therapy; Female; Gene expression; Gene Expression Regulation, Neoplastic; Gene silencing; Genes; Genetic aspects; Helper cells; Humans; Immunohistochemistry; Immunosuppressive agents; Infiltration; Leukocytes (eosinophilic); LUAD; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Lymphocytes T; Male; Mast cells; Medical prognosis; Metastases; Middle Aged; Nomograms; Oncology, Experimental; p53 Protein; Patients; Prognosis; Proteins; Regression analysis; RNA-mediated interference; Sensitivity; Sensitivity analysis; Stem cells; Survival analysis; Tumors; China; CDCA8; Biomarker; Sensitivity; Prognosis; LUAD